These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation. Wei XC; Zhao MF; Li X; Xiao X J Clin Pharmacol; 2020 Jun; 60(6):768-774. PubMed ID: 32080861 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration. da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753 [TBL] [Abstract][Full Text] [Related]
4. Optimization of dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant Wei X; Zhao M; Xiao X J Chemother; 2021 Dec; 33(8):547-553. PubMed ID: 34080519 [TBL] [Abstract][Full Text] [Related]
5. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Falcone M; Russo A; Venditti M; Novelli A; Pai MP Clin Infect Dis; 2013 Dec; 57(11):1568-76. PubMed ID: 24046298 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. Soon RL; Turner SJ; Forrest A; Tsuji BT; Brown J Int J Antimicrob Agents; 2013 Jul; 42(1):53-8. PubMed ID: 23684388 [TBL] [Abstract][Full Text] [Related]
7. Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia. Arrieta AC; Bradley JS; Popejoy MW; Bensaci M; Grandhi A; Bokesch P; Glasser C; Du L; Patino H; Kartsonis NA Pediatr Infect Dis J; 2018 Sep; 37(9):893-900. PubMed ID: 29406465 [TBL] [Abstract][Full Text] [Related]
8. PK/PD modeling of daptomycin against MRSA and MRSE and Monte Carlo simulation for bacteremia treatment. Menezes B; Alves I; Staudt K; Beltrame B; Michelin L; de Araújo BV; Tasso L Braz J Microbiol; 2021 Dec; 52(4):1967-1979. PubMed ID: 34337679 [TBL] [Abstract][Full Text] [Related]
9. A Pharmacokinetic-Pharmacodynamic Analysis to Dose Optimize Daptomycin in Vancomycin-Resistant Butterfield-Cowper JM Ann Pharmacother; 2021 Jul; 55(7):846-855. PubMed ID: 33147997 [TBL] [Abstract][Full Text] [Related]
10. Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial. Kalimuddin S; Phillips R; Gandhi M; de Souza NN; Low JG; Archuleta S; Lye D; Tan TT Trials; 2014 Jun; 15():233. PubMed ID: 24943129 [TBL] [Abstract][Full Text] [Related]
11. Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis. Yamada T; Ooi Y; Oda K; Shibata Y; Kawanishi F; Suzuki K; Nishihara M; Nakano T; Yoshida M; Uchida T; Katsumata T; Ukimura A J Infect Chemother; 2020 Apr; 26(4):379-384. PubMed ID: 31836287 [TBL] [Abstract][Full Text] [Related]
12. Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. De Gregori S; De Silvestri A; Molinaro MD; Monzillo V; Biscarini S; Colaneri M; Gallazzi I; Bartoli A; Bruno R; Seminari E Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):547-554. PubMed ID: 34231117 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Rose WE; Leonard SN; Rybak MJ Antimicrob Agents Chemother; 2008 Sep; 52(9):3061-7. PubMed ID: 18591272 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations. Bhavnani SM; Ambrose PG; Hammel JP; Rubino CM; Drusano GL Antimicrob Agents Chemother; 2015 Dec; 60(3):1600-7. PubMed ID: 26711755 [TBL] [Abstract][Full Text] [Related]
16. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Butterfield JM; Mueller BA; Patel N; Cardone KE; Grabe DW; Salama NN; Lodise TP Antimicrob Agents Chemother; 2013 Feb; 57(2):864-72. PubMed ID: 23208714 [TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study. Kalimuddin S; Chan YFZ; Phillips R; Ong SP; Archuleta S; Lye DC; Tan TT; Low JGH Trials; 2018 Jun; 19(1):305. PubMed ID: 29859132 [TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations. Martins FS; Martins JES; Severino P; Annaert P; Sy SKB Br J Clin Pharmacol; 2023 Sep; 89(9):2726-2738. PubMed ID: 37005335 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of daptomycin in Japanese pediatric participants with complicated skin and soft tissue infections or bacteremia caused by gram-positive cocci. Iwata S; Koyama H; Murata Y J Infect Chemother; 2022 Mar; 28(3):406-412. PubMed ID: 34920946 [TBL] [Abstract][Full Text] [Related]
20. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]